Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Issue 11 (2nd November 2019)

• Record Type: Journal Article
• Authors: Ali, Monadil H; Alrasheedy, Alian A; Kibuule, Dan; Godman, Brian; Hassali, Mohamed Azmi; Ali, Hamdan Mustafa Hamdan
• Is Part Of: Expert review of anti-infective therapy. Volume 17:Issue 11(2019)
• Page Start: 927
• Page End: 937
• Publication Date: 2019-11-02
• Subjects: Multidrug-resistant tuberculosis -- treatments -- outcomes -- predictors -- rural populations -- Sudan; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2019.1689818
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Background : Multidrug-resistant tuberculosis (MDR-TB) has a socioeconomic impact and threatens global public health. We assessed treatment outcomes of MDR-TB and predictors of poor treatment outcomes in Sudan given current high prevalence rates. Methods : Combined retrospective and prospective cohort study at Abu-Anga hospital (TB specialized hospital in Sudan). All patients with MDR-TB between 2013 and 2017 were targeted. Results : A total of 156 patients were recruited as having good records, 117 (75%) were male, and 152 (97.4%) had pulmonary TB. Patients were followed for a median of 18 months and a total of 2108 person-months. The overall success rate was 63.5% and the mortality rate was 14.1%. Rural residency (P < 0.05) and relapsing on previous treatments (P < 0.05) were determinants of time to poor MDR-TB treatment outcomes. Conclusion : Overall, more attention needs to be given to special MDR-TB groups that are highly susceptible to poor outcomes, i.e. rural patients. As a result, it is highly recommended to maintain total coverage of medicines for all MDR-TB patients for the entire period of treatment in Sudan. It is also recommended to instigate more treatment centers in rural areas in Sudan together with programs to enhance adherence to treatments including patient counseling to improve future outcomes.